This page shows the latest Tcelna news and features for those working in and with pharma, biotech and healthcare.
It also has a licensing deal in place for Tcelna (imilecleucel-T), a personalised treatment for secondary-progressive MS developed by Opexa Therapeutics that is in phase IIb testing with
Overall groups sales down to €2.84bn for second quarter of 2013
and recently-licensed MS drug Tcelna (imilecleucel-T) following the decision to drop brain and lung cancer prospect cilengitide from development in the first quarter.
Will develop personalised T-cell based medicine Tcelna. Merck KGaA has agreed a deal with Opexa Therapeutics to develop and commercialise a new personalised treatment for multiple sclerosis (MS). ... During the SPMS trial, patients undergo two annual
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
sales. In the other option deal, Merck Serono has acquired an option over Opexa Therapeutics' phase IIb Tcelna (imilecleucel-T) vaccine for MS (for all territories except Japan). ... Tcelna is being developed as a personalised therapy specifically
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...